Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Parmiani

Showing results (91-100 of 301) with videos related to

Pageof 31
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1994
Gene transfer in tumor therapyG Forni, G Parmiani, A Guarini, et al.
International Journal of Cancer|September 15, 1990
Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive abilityA Anichini, R Mortarini, R Supino, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectorsM Sensi, L Grazioli, M Rodolfo, et al.
International Journal of Clinical & Laboratory Research|January 1, 1997
T-cell recognition of melanoma antigens and its therapeutic applicationsC Castelli, L Rivoltini, A Mazzocchi, et al.
Cancer Research|November 24, 2001
Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cellsG Pietra, R Mortarini, G Parmiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Vaccination of patients with solid tumoursG Parmiani, L Pilla, C Castelli, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicinR Supino, M Mariani, E Prosperi, et al.
International Journal of Cancer|February 15, 1990
Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinationsR Mortarini, F Belli, G Parmiani, et al.
International Journal of Cancer|December 15, 1990
Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicityM Sensi, M Bergomi, F Formelli, et al.
Melanoma Research|July 1, 1992
Can oncogene (RAS) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to adoptive immunotherapy?G Parmiani, A Anichini, G Carbone, et al.
Pageof 31

Showing results (91-100 of 301) with videos related to

Sort By:
Pageof 31
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1994
Gene transfer in tumor therapyG Forni, G Parmiani, A Guarini, et al.
International Journal of Cancer|September 15, 1990
Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive abilityA Anichini, R Mortarini, R Supino, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectorsM Sensi, L Grazioli, M Rodolfo, et al.
International Journal of Clinical & Laboratory Research|January 1, 1997
T-cell recognition of melanoma antigens and its therapeutic applicationsC Castelli, L Rivoltini, A Mazzocchi, et al.
Cancer Research|November 24, 2001
Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cellsG Pietra, R Mortarini, G Parmiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Vaccination of patients with solid tumoursG Parmiani, L Pilla, C Castelli, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicinR Supino, M Mariani, E Prosperi, et al.
International Journal of Cancer|February 15, 1990
Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinationsR Mortarini, F Belli, G Parmiani, et al.
International Journal of Cancer|December 15, 1990
Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicityM Sensi, M Bergomi, F Formelli, et al.
Melanoma Research|July 1, 1992
Can oncogene (RAS) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to adoptive immunotherapy?G Parmiani, A Anichini, G Carbone, et al.
Pageof 31